These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

303 related items for PubMed ID: 9211018

  • 21. Associations between lipoproteins and the progression of coronary and vein-graft atherosclerosis in a controlled trial with gemfibrozil in men with low baseline levels of HDL cholesterol.
    Syvänne M, Nieminen MS, Frick MH, Kauma H, Majahalme S, Virtanen V, Kesäniemi YA, Pasternack A, Ehnholm C, Taskinen MR.
    Circulation; 1998 Nov 10; 98(19):1993-9. PubMed ID: 9808595
    [Abstract] [Full Text] [Related]

  • 22. The Monitored Atherosclerosis Regression Study (MARS). Design, methods and baseline results.
    Cashin-Hemphill L, Kramsch DM, Azen SP, DeMets D, DeBoer LW, Hwang I, Vailas L, Hirsch LJ, Mack WJ, DeBoer L.
    Online J Curr Clin Trials; 1992 Oct 23; Doc No 26():[9897 words; 83 paragraphs]. PubMed ID: 1343613
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
    Tenenbaum A, Fisman EZ, Motro M, Adler Y.
    Adv Cardiol; 2008 Oct 23; 45():127-153. PubMed ID: 18230960
    [Abstract] [Full Text] [Related]

  • 25. Treatment of dyslipidaemias in patients with established vascular disease: a revival of the fibrates.
    Milionis HJ, Elisaf MS, Mikhailidis DP.
    Curr Med Res Opin; 2000 Oct 23; 16(1):21-32. PubMed ID: 16422031
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group.
    Frick MH, Syvänne M, Nieminen MS, Kauma H, Majahalme S, Virtanen V, Kesäniemi YA, Pasternack A, Taskinen MR.
    Circulation; 1997 Oct 07; 96(7):2137-43. PubMed ID: 9337181
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Efficacy and tolerability of fluvastatin and bezafibrate in patients with hyperlipidemia and persistently high triglyceride levels.
    Spieker LE, Noll G, Hannak M, Lüscher TF.
    J Cardiovasc Pharmacol; 2000 Mar 07; 35(3):361-5. PubMed ID: 10710119
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Prevention and regression of atherosclerosis: effects of HMG-CoA reductase inhibitors.
    Bjelajac A, Goo AK, Weart CW.
    Ann Pharmacother; 1996 Nov 07; 30(11):1304-15. PubMed ID: 8913414
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ.
    Atheroscler Suppl; 2011 Nov 07; 12(3):277-84. PubMed ID: 22152282
    [Abstract] [Full Text] [Related]

  • 39. Efficacy and safety of triple therapy (fluvastatin-bezafibrate-cholestyramine) for severe familial hypercholesterolemia.
    Leitersdorf E, Muratti EN, Eliav O, Peters TK.
    Am J Cardiol; 1995 Jul 13; 76(2):84A-88A. PubMed ID: 7604807
    [Abstract] [Full Text] [Related]

  • 40. Relation of clinical benefit to metabolic effects in lipid-lowering therapy.
    Herd JA.
    Am J Cardiol; 1998 Sep 24; 82(6A):22M-25M. PubMed ID: 9766344
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.